StockNews.AI
DAVE
StockNews.AI
119 days

Valneva SE Company Investigated by the Portnoy Law Firm

1. Portnoy Law Firm investigates potential securities fraud regarding Valneva (DAVE). 2. Legal claims may be filed for investors who lost money on DAVE. 3. CDC is reviewing adverse events linked to Valneva's chikungunya vaccine IXCHIQ. 4. Valneva's ADR dropped by 13.57% following adverse event reports. 5. Investors can contact Portnoy Law Firm for legal consultation.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The investigation into possible securities fraud and adverse health reports can lead to significant investor distrust and sell-off, reminiscent of past cases like Valeant Pharmaceuticals where headlines of fraud led to dramatic price drops.

How important is it?

The ongoing investigation directly involves DAVE's financial stability, potentially impacting investor confidence and stock valuation quickly.

Why Short Term?

Given the immediate negative news regarding health incidents and potential lawsuits, DAVE's price is likely to experience downturn in the coming weeks, similar to previous rapid price declines following legal investigations.

Related Companies

VALNVRNANVAX
LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Valneva SE (“Valneva” or “the Company”) (NASDAQ: DAVE) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Dave investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. On February 25, 2025, the U.S. Centers for Disease Control and Prevention (CDC) published a notice on its website stating that it was investigating five cases of hospitalization involving cardiac or neurological events in individuals aged 65 and older who had received IXCHIQ, Valneva’s chikungunya virus vaccine. Following this announcement, along with subsequent media coverage, the price of Valneva’s American Depositary Receipts (ADRs) declined by $1.06, or approximately 13.57%, over the next four trading days, closing at $6.75 per ADR on February 28, 2025. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA, NY and TX Barslesley@portnoylaw.com310-692-8883www.portnoylaw.com Attorney Advertising

Related News